PTGDR and central nervous system cancer: Figure 1(a) demonstrates the obviously lower ELF3-AS1 expression in tumor tissues relative to noncancerous tissues (p < 0.01). In addition, we observed that the glioma specimens with advanced stages exhibited a higher level of ELF3-AS1 than those with early stages (Figure 1(b)). Moreover, we examined the levels of ELF3-AS1 in four glioma cell lines, finding that ELF3-AS1 expression levels were increased in four glioma cell lines compared with NHA, particularly in H4 and LN229 cells (Figure 1(c), p < 0.05).